Published: 14 September 2022
Archived: 21 August 2024

About Medsafe

COVID-19 Archive

Adverse events following immunisation with COVID-19 vaccines: Safety Report #45 – 31 August 2022

Medsafe advises people NOT to make any decisions about vaccination based on information contained in this report. If you have questions or concerns about receiving a vaccine, please speak to a health care professional.

• What you need to know
• Introduction
• Adverse events following immunisation (AEFI) reported
• Summary of reported deaths
• Observed versus expected analyses
• Adverse events of special interest
• Summary of safety signals
• Definitions
• More information

What you need to know – up to and including 31 August 2022

Note that counts may change due to receipt of additional information.

For the Comirnaty (Pfizer) vaccine

For the Vaxzevria (AstraZeneca) vaccine

• The protective benefits of vaccination against COVID-19 far outweigh the potential risks of vaccination.
• The Ministry of Health, the National Immunisation Programme, Medsafe, the Centre for Adverse Reactions Monitoring and manufacturers continue to closely monitor the safety of COVID-19 vaccines. We’ll respond to any safety issues right away and will inform New Zealanders about any risks that arise in New Zealand.
• For more information about Covid Vaccine Immunisation Programme, please go to Unite against COVID-19 or call Healthline 0800 611 116 to talk to someone about your concerns.
• Comirnaty: There were 1,026 non-serious and 98 serious reports since the last update. Sadly, have 6 further notifications of death to report. Any possibility of a causal link is investigated as part of our routine investigations and no new safety concerns with the Comirnaty vaccine were raised by these 6 reports. For information about reported deaths, please refer to the summary of reported deaths.
• Vaxzevria: The vaccine became available on 26 November 2021. Up to 31 August 2022, there have been 298 non-serious and 21 serious reports for the Vaxzevria vaccine, including 6 non-serious and no serious reports since the last update. There have been no notifications of death.
• Comirnaty: Up to 31 August 2022 a total of 11,682,248 doses of Comirnaty have been administered and 64,061 AEFIs were reported. This means that more than 11.61 million doses of Comirnaty were administered that did not result in a report of an adverse event. On average for every 10,000 people who are vaccinated 55 people report an AEFI. It is also important to keep in mind that a report can be submitted for any cause and is not necessarily associated with the vaccine.
• Vaxzevria: Up to 31 August 2022, a total of 9,087 doses of Vaxzevria vaccine have been administered and 319 AEFIs were reported. This means that more than 8,750 doses of Vaxzevria vaccine were administered that did not result in a report of an adverse event. On average for every 10,000 people who are vaccinated 351 people report an AEFI. It is also important to keep in mind that a report can be submitted for any cause and is not necessarily associated with the vaccine.
• Nuvaxovid: The Nuvaxovid COVID-19 vaccine became available in New Zealand on 18 March 2022. Up to 31 August 2022, 5,891 doses of the vaccine had been administered and 72 AEFI reports were submitted. We will provide more information about this vaccine in future safety reports.
• Nuvaxovid Safety Alert: Medsafe has issued an alert communication about reports of myocarditis and pericarditis following immunisation with Nuvaxovid.
• The next safety report (#46) will be published on 14 December 2022, for the period ending 30 November 2022.

Introduction

The national roll-out of COVID-19 vaccines commenced on 20 February 2021 with Pfizer-BioNTech (Comirnaty). The AstraZeneca vaccine (also known as Vaxzevria) became available on 26 November 2021, and Nuvaxovid on 18 March 2022.

This page provides information on the number of adverse events following immunisation (AEFI) reports received for COVID-19 vaccines.

An AEFI is an untoward medical event which follows immunisation and does not necessarily have a causal relationship with the administration of the vaccine. The adverse event may be an unfavourable or unintended sign, abnormal laboratory finding, symptom or disease.

All medicines can cause side effects, the known side effects for COVID-19 vaccines are listed in the data sheets and consumer medicine information (CMI).

Search for a data sheet or CMI

Suspected AEFI to COVID-19 vaccines are reported to the Centre for Adverse Reactions Monitoring (CARM). The Ministry of Health (through Medsafe) contracts the collection of this information to CARM, based at the University of Otago in Dunedin. Medsafe is closely monitoring the AEFI reported from the use of the COVID-19 vaccine. Find out more about vaccine safety monitoring.

Medsafe and CARM thank everyone who has contributed to the monitoring of COVID-19 vaccines. Please continue to report any adverse events following immunisation.

Adverse events following immunisation (AEFI) reported

The information below includes:

• AEFI reports by prioritised ethnicity and vaccine dose
• AEFI reports by age band and vaccine dose
• the top 10 most frequently reported AEFIs by vaccine dose
• reported AEFIs by reporter type.

Table 1: AEFI reports received by prioritised ethnicity and vaccine dose, by vaccine, up to and including 31 August 2022

Ethnicitya	Comirnaty				Vaxzevria
	Dose 1	Dose 2	Dose 3	Total	Total
Māori	2,707	2,149	932	5,788	31
Pacific Peoples	816	774	310	1,900	3
Asian	2,812	2,332	1,371	6,515	12
European or other	21,169	18,084	9,405	48,658	268
Unknownb	297	196	71	564	5
Total	27,801	23,535	12,089	63,425c	319d

Notes:

1. The prioritised ethnicity classification system allocates each person to a single ethnic group, based on the ethnic groups they identify with. Where people identify with more than one group, they are assigned in this order of priority: Māori, Pacific Peoples, Asian, and European/Other. So, if a person identifies as being Māori and New Zealand European, the person is counted as Māori. See Ethnicity Data Protocols for further information.
2. There were 564 Comirnaty and 5 Vaxzevria AEFI reports where the person’s ethnicity was not reported. Counts may change due to receipt of additional information. Ethnicity is not required for an AEFI report to be considered valid. See ‘Valid report’ in the Definitions section below.
3. The Comirnaty total is different from the cumulative total above because this table only includes reports following dose 1, 2, and 3. The table also excludes 22 AEFI reports received for infants who did not receive the vaccine. Dose 4 will be included once more reports have been received.
4. Due to the low numbers of reports to date, only totals for Vaxzevria are shown to protect privacy.

Table 2: AEFI reports received by age band and vaccine dose, by vaccine, up to and including 31 August 2022

Age	Comirnaty				Vaxzevria
	Dose 1	Dose 2	Dose 3	Total	Total
5 - 11 years	628	199	0	827	0
12 - 19 years	2,843	1,768	288	4,899	10
20 - 29 years	5,356	4,101	2,171	11,628	41
30 - 39 years	6,024	5,146	2,762	13,932	71
40 - 49 years	4,767	4,501	2,461	11,729	81
50 - 59 years	4,041	3,811	2,166	10,018	80
60 - 69 years	2,447	2,326	1,336	6,109	27
70 - 79 years	1,168	1,183	643	2,994	7
80+ years	496	488	258	1,242	2
Unknowna	31	12	4	47	0
Total	27,801	23,535	12,089	63,425b	319c

Notes:

1. There were 47 Comirnaty AEFI reports where the person’s age was not reported. Counts may change due to receipt of additional information. Age is not required for an AEFI report to be considered valid. See ‘Valid report’ in the Definitions section below.
2. The Comirnaty total is different from the cumulative total above because this table only includes reports following dose 1, 2, and 3. The table also excludes 22 AEFI reports received for infants who did not receive the vaccine. Dose 4 will be included once more reports have been received
3. Due to the low numbers of reports to date, only totals for Vaxzevria are shown to protect privacy.

Figure 1: Top 10 most frequently reported AEFIs for the Comirnaty vaccine, by dose, up to and including 31 August 2022

Figure 2: Top 10 most frequently reported AEFIs for the Vaxzevria vaccine, any dose, up to and including 31 August 2022

Download a list of the top 50 most frequently reported AEFIs (any dose) (Excel 21 KB).

Table 5: Reported AEFIs by reporter type (any vaccine) up to and including 31 August 2022

Reporter type	Number of reportsa
Public Patient	26,762
CIR Vaccinator	15,109
Nurse	8,651
Other	6,327
General Practitioner	8,574
Public: On behalf of a patient	2,223
Pharmacist	382
Not specified	115

1. The total number here differs from the total reported cases elsewhere because a single case can contain multiple reports from different sources.

Please note that one adverse event report, which represents one person, may report on more than one symptom. Reports are sent to CARM if the reporter suspects that the vaccine may have caused the event. This does not necessarily mean that the vaccine did cause the event.

The number of reports can be influenced by how many people are being vaccinated, media attention, the nature of the events (eg, how painful the vaccination was), and other factors which vary over time. Not everyone who has an adverse reaction reports it, and some people may report AEFIs after each vaccination. The information here shows the number of reports not the number of people who experienced an AEFI.

The information is limited by the information provided in the report and may change over time due to quality control procedures and/or receipt of additional information. Non-valid reports are not included in the data.

Summary of reported deaths

Up to and including 31 August 2022, a total of 177 deaths were reported to CARM after the administration of the Comirnaty vaccine. Following medical assessments by CARM and Medsafe it has been determined that:

• 159 of these deaths are unlikely related to the COVID-19 vaccine
• 7 deaths could not be assessed due to insufficient information
• 8 cases are still under investigation
• 1 death was determined by the Coroner to be due to myocarditis following first dose Covid-19 (Pfizer) vaccination
• 2 deaths were likely due to vaccine induced myocarditis (awaiting Coroner’s determination).

By chance, some people will experience new illnesses or die from a pre-existing condition shortly after vaccination, especially if they are elderly. Therefore, part of our review process includes comparing natural death rates to observed death rates following vaccination, to determine if there are any specific trends or patterns that might indicate a vaccine safety concern. See below for more information about these observed-versus-expected analyses.

To date, the observed number of deaths reported after vaccination is actually less than the expected number of natural deaths.

There have been no deaths reported for the Vaxzevria or Nuvaxovid vaccines.

Table 6: Mortalities by age group up to and including 31 August 2022 reported to CARM, Comirnaty vaccine

Age	Mortalitiesa
10 - 29 years	9
30 - 59 years	34
60 - 79 years	81
80+ years	53

1. Counts may change due to receipt of additional information, for example, identification of duplicate reports.

Observed-versus-expected analyses – Comirnaty vaccine

It is important to note that no conclusions should be made from these observed-versus-expected analyses in isolation. Other investigations looking at pre-existing risk factors are always required.

The analyses below show that the number of deaths recorded in the mortality register for people vaccinated with the Comirnaty vaccine is lower than expected based on the average number of deaths in previous years over the same number of days (natural death rate).

For these observed-versus-expected analyses, we compare the vaccinated population to natural (expected) rates (taken from past data). The comparison is done by dividing the observed rate of death in the vaccinated population by the expected rate to give the relative risk (RR).

Observed / Expected Rate = Relative Risk (RR)

The methods used to calculate the relative risk also provide a confidence interval (CI). The confidence interval is a range of values that we are fairly sure our true value lies in. We are using a 95 percent confidence interval (95% CI), which is the range that will include the true value 95 percent of the time. If both the relative risk AND the lower end of the confidence interval are greater than one (>1.0), this is statistically significant and could indicate an increased risk of death in the vaccinated population. This will be highlighted in the table when applicable.

We are monitoring people for 21 days after vaccination. This monitoring period was chosen because people can receive their second dose a minimum of 21 days after the first dose. Age-specific natural (expected) death rates were obtained for the period 2008–2019. One reason for the number of deaths in the vaccinated group appearing to be lower could be that healthcare professional of extremely frail patients give the advice not to get vaccinated.

These analyses do not consider causality and instead, report on all deaths that have occurred in the monitoring period (observed deaths). This results in a much higher number than those reported to CARM where the reporter (eg, family member or health care provider) might have had a suspicion the vaccine could have played a role. The number of observed deaths also includes deaths from other causes, such as deaths due to accidents, medical conditions, other medicines or medical treatments.

Please note that the mortality collections operate many weeks in arrears. This means that these observed-versus-expected analyses will also be in arrears – for example, the tables below are for the period up to 30 June 2022.

Table 7: Observed-versus-expected deaths^a by age group from any cause, up to 21 days after Comirnaty dose 1, 19 February 2021 to 30 June 2022

Age	Dose 1 – number administered	Expected deathsb in monitoring period	Observed deathsc in monitoring period	Relative riskc (95% confidence interval)
0 to 9	179,237	6.27	0	- d
10 to 19	584,435	10.94	12	1.10e [0.57 – 1.92]
20 to 29	651,499	22.62	24	1.06f [0.68 – 1.58]
30 to 39	677,516	31.17	14	0.45 [0.25 – 0.75]
40 to 49	593,284	57.56	24	0.42 [0.27 – 0.62]
50 to 59	608,436	135.77	64	0.47 [0.36 – 0.60]
60 to 69	516,903	269.49	128	0.47 [0.40 – 0.56]
70 to 79	349,460	492.19	240	0.49 [0.43 – 0.55]
80+	182,823	1,083.85	606	0.56 [0.52 – 0.61]
Total	4,343,593	2,109.86	1,112	0.53 [0.50 – 0.56]

1. Expected and observed deaths among people who have received dose 1 of the Comirnaty vaccine during the specified period, by age group. Inclusion criteria were: monitoring time of 21 days after receiving dose 1, all genders, all ethnicities, aged 5 years and older. The data was collected from the Mortality database.
2. Data for expected death rates was obtained from the AESI background rate (SAFE) study provided by the University of Auckland (however, please note that the publicly available information only shows rates of sudden death not all deaths). The age-specific background rates used are the average from 2008-2019.
3. The observed deaths column (4th column) is a raw data observation, and this is used to calculate the relative risk (5th column).
4. The relative risk has not been calculated for the 0 - 9 years age group because no deaths were observed during the monitoring period.
5. The relative risk of 1.10 does not indicate there is an increased risk of mortality in the 10 - 19 age group because the lower end of the confidence interval is 0.57 (ie, <1.0). The COVID-19 Independent Safety Monitoring Board (CV-ISMB) has reviewed AEFIs in children and found that this group was not disproportionately affected by the vaccine. Medsafe will continue to monitor this closely.
6. The relative risk of 1.06 does not indicate there is an increased risk of mortality in the 20 - 29 year age group because the lower end of the confidence interval is 0.68 (ie, <1.0).

Table 8: Observed-versus-expected deaths^a by age group from any cause, up to 21 days after Comirnaty dose 2, 19 February 2021 to 30 June 2022

Age	Dose 2 – number administered	Expected deathsb in monitoring period	Observed deathsc in monitoring period	Relative riskc (95% confidence interval)
0 to 9	85,659	2.93	0	- d
10 to 19	529,527	9.89	10	1.01e [0.48 – 1.86]
20 to 29	640,326	22.23	7	0.31 [0.13 – 0.65]
30 to 39	669,255	30.79	16	0.52 [0.30 – 0.84]
40 to 49	586,878	56.94	33	0.58 [0.40 – 0.81]
50 to 59	604,593	134.90	85	0.63 [0.50 – 0.78]
60 to 69	516,036	268.97	152	0.57 [0.48 – 0.66]
70 to 79	349,585	492.31	218	0.44 [0.39 – 0.51]
80+	182,584	1,082.39	625	0.58 [0.53 – 0.62]
Total	4,164,443	2,101.35	1,146	0.55 [0.51 – 0.58]

1. Expected and observed deaths among people who have received dose 2 of the Comirnaty vaccine during the specified period, by age group. Inclusion criteria were: monitoring time of 21 days after receiving dose 2, all genders, all ethnicities, aged 5 years and older. The data was collected from the Mortality database.
2. Data for expected death rates was obtained from the AESI background rate (SAFE) study provided by the University of Auckland (however, please note that the publicly available information only shows rates of sudden death not all deaths). The age-specific background rates used are the average from 2008-2019.
3. The observed deaths column is a raw data observation, and this is used to calculate the relative risk (5th column).
4. The relative risk has not been calculated for the 0 - 9 age group because no deaths were observed during the monitoring period.
5. The relative risk of 1.01 does not indicate there is an increased risk of mortality in the 10 - 19 age group because the lower end of the confidence interval is 0.48 (ie, <1.0). The COVID-19 Independent Safety Monitoring Board (CV-ISMB) has reviewed AEFIs in children and found that this group was not disproportionately affected by the vaccine. Medsafe will continue to monitor this closely.

Table 9: Observed-versus-expected deaths^a by age group from any cause, up to 21 days after Comirnaty dose 3, 19 February 2021 to 30 June 2022

Age	Dose 3 – number administered	Expected deathsb in monitoring period	Observed deathsc in monitoring period	Relative riskc (95% confidence interval)
10 to 19	75,602	1.39	0	- d
20 to 29	333,952	11.53	<6	- e
30 to 39	414,077	18.97	8	0.42 [0.18 - 0.83]
40 to 49	421,066	40.74	15	0.37 [0.21 – 0.61]
50 to 59	482,261	107.39	55	0.51 [0.39 – 0.67]
60 to 69	454,654	236.66	106	0.45 [0.37 – 0.54]
70 to 79	328,058	461.57	208	0.45 [0.39 – 0.52]
80+	175,420	1,038.96	539	0.52 [0.48 – 0.56]
Total	2,685,090	1,917.21	933	0.49 [0.46 – 0.52]

1. Expected and observed deaths among people who have received dose 3 (including the ‘booster’ dose) of the Comirnaty vaccine during the specified period, by age group. Inclusion criteria were: monitoring time of 21 days after receiving dose 3, all genders, all ethnicities, aged 12 years and older. The data was collected from the Mortality database.
2. Data for expected death rates was obtained from the AESI background rate (SAFE) study provided by the University of Auckland (however, please note that the publicly available information only shows rates of sudden death not all deaths). The age-specific background rates used are the average from 2008-2019.
3. The observed deaths column (4th column) is a raw data observation, and this is used to calculate the relative risk (5th column).
4. The relative risk has not been calculated for the 10 - 19 year olds because no deaths were observed during the monitoring period.
5. The relative risk has not been calculated for the 20 - 29 year olds because fewer than six deaths have occurred in this age group.

For further reading about the methodology used to analyse death rates, see:

• Centers for Disease Control and Prevention (CDC) – Rapid Cycle Analysis (RCA) to monitor the safety of COVID-19 vaccines in near real-time within the Vaccine Safety Datalink. URL: https://www.cdc.gov/vaccinesafety/pdf/VSD-1342-COVID19-RCA-Protocol_FinalV1.1_508.pdf
• Kulldorff M, Davis RL, Kolczak M, et al. A maximised sequential probability ratio test for drug and vaccine safety surveillance. Sequential Analysis 30(1): 58–78. URL: https://www.tandfonline.com/doi/full/10.1080/07474946.2011.539924.

Download the data used to calculate the number of expected deaths in the monitoring period:

Expected mortality data (Excel 22 KB)

Adverse events of special interest

Adverse events of special interest (AESI) are pre-specified medically significant events that have the potential to be causally associated with the vaccine and must be carefully monitored. AESI can be serious or non-serious and can include:

• Events of interest due to their association with COVID-19 infection
• Events of interest for vaccines in general (eg, to the specific vaccine type or adjuvants).

The list of AESIs below takes into consideration the lists of AESIs from expert groups such as the Brighton Collaboration, manufacturers and other regulatory authorities. The AESI list changes based on the evolving safety profile of vaccines. It is important to note that although these adverse events may occur after being vaccinated with a COVID-19 vaccine in New Zealand, they are rare and may not necessarily be related to the vaccine. Medsafe and CARM review the reports to determine whether the vaccine may have played a role in the occurrence of these events.

Table 10: Adverse events of special interest (AESI) up to and including 31 August 2022

AESI Category	AESI	Comirnaty totala	Vaxzevria totala	Background rate (hospitalisations per year)b
Immune system disorders	Guillain-Barré Syndrome	34	0	273
	Thrombocytopenia	38	<6	4,325
	Thrombosis with thrombocytopenia syndrome (TTS)	n/ac	0
	Anaphylaxisd	127	<6	1,102
Cardiovascular system	Myocardial infarction (heart attack)	99	0	16,347
	Myocarditis/pericarditis	944	<6	931
Blood and lymphatic system	Thrombosis	61	0	2,863
	Embolism	159	<6	4,571
	Deep vein thrombosis (DVT)	126	<6	519
	Vasculitis	74	0	4,325
	Haemorrhagee	165	0
Hepato-gastrointestinal and renal system	Acute kidney injury	30	0	38,631
	Acute liver injury	8	0	420
	Pancreatitisf	15	0	3,359
	Appendicitisg	23	0	6,048
Nervous system	Aseptic meningitis	<6	0	744
	Encephalitis	12	0	409
	Stroke	130	0	14,776
	Bell's Palsy/facial paralysis	226	<6	694
	Myelitis/myelitis transverse	9	0	53
Infections and musculoskeletal	Erythema multiforme	20	0	97
	Arthritis	127	0	178
	Herpes zoster	406	<6	1,148
Pregnancy, puerperium and perinatal conditions	Abortion (spontaneous abortion /miscarriage)h	66	0	2,680

1. Includes all AESI reports, both serious and non-serious. Counts below 6 are reported as <6 for privacy reasons. Counts may change due to receipt of additional information and subsequent reclassification of cases.
2. AESI background hospitalisation rates used to estimate the expected number of events in the general population, which help in vaccine safety surveillance. Counts indicate average of hospitalisation rates for the calendar years 2016-2019.
3. The thrombosis with thrombocytopenia syndrome (TTS) AESI occurs only in non-replicating viral vaccines (eg, the Vaxzevria vaccine)
4. Includes anaphylaxis reports meeting levels 1-3 of the Brighton Collaboration case definition.
5. Haemorrhage can manifest in different ways depending on the mechanism and anatomic location. It is difficult to know if the haemorrhage was minor or significant through the hospitalisation background rates.
6. The background rate for pancreatitis has been changed since the last report to reflect the results of a review of the ICD-10 codes used to generate the background rates.
7. The background rate for appendicitis has been changed since the last report to reflect the results of a review of the ICD-10 codes used to generate the background rates.
8. The background rate for abortion (spontaneous abortion/miscarriage) has been changed since the last report to reflect the results of a review of the ICD-10 codes used to generate the background rates.

Download a list of all ICD-10 codes used to produce the hospitalisation rates for Table 10.

ICD-10 Codes (Excel, 23 KB)

Further information on Myocarditis and Pericarditis

Myocarditis is inflammation of the heart muscle, while pericarditis is inflammation of the tissue forming a sac around the heart. Myo-pericarditis means that both the heart muscle and the sac are inflamed.

There are many possible causes of myocarditis, the most common being viral infection. New Zealand data from the Global Vaccine Data Network indicates that the background rate of non-infective myocarditis (pre COVID-19) in the overall population from 2011 to 2019 was 1.81 per 100,000 person-years.

Up to 31 August 2022, the Centre for Adverse Reactions Monitoring (CARM) has received 500 spontaneous reports of myocarditis, pericarditis or myopericarditis where the report contained evidence of a clinical diagnosis and the symptom onset time was within 30 days of vaccination (to reduce the risk of including coincidental cases). These reports do not necessarily have a causal relationship with administration of Comirnaty and may represent coincidental events. The age ranges, by dose number, are shown in Figure 3. Of the 500 reports, 62% were for males. Thirty-one percent of reports were associated with dose one, 46% of reports were associated with dose two and 22% reported that the myocarditis/pericarditis was experienced after dose three.

Figure 3: Ages of people reported with myocarditis/pericarditis after Comirnaty vaccination in New Zealand, by dose number, up to 31 August 2022

Summary of safety signals

Comirnaty: There has been one new safety signal identified since the last safety report (vasculitis).

Nuvaxovid: Medsafe has issued an alert communication about reports of myocarditis and pericarditis following immunisation with Nuvaxovid.

Medsafe will continue to monitor reports for safety signals through routine pharmacovigilance.

Table 12: Summary of Medsafe’s investigations into possible safety signals

Safety signal	Outcome
Comirnaty vaccine
Blood clots	Continue to monitor. See also the Monitoring communication
Appendicitis	Continue to monitor
Myocarditis/pericarditis	Information has been added to Comirnaty data sheet. See also the Alert communication. Medsafe will continue to monitor this closely.
Herpes zoster	Continue to monitor
Bell’s palsy/facial paralysis	Continue to monitor
Menstrual disorder	Continue to monitor. See also the monitoring communication.
Stroke	Continue to monitor
Tinnitus	Continue to monitor
AEFIs in the elderly	Continue to monitor and updated data sheet
Pancreatitis	Continue to monitor
Glomerular diseases	Continue to monitor
Guillain-Barré Syndrome	Continue to monitor
Thrombocytopenia	Continue to monitor
AEFIs in children	Continue to monitor
Erythema multiforme	Continue to monitor
Pregnancy	Continue to monitor. See also the monitoring communication.
Persisting disability	Continue to monitor
Thyroid conditions	Continue to monitor
Vasculitis	Continue to monitor
Vaxzevria vaccine
Overview of AEFI reports to date	No safety signals identified
Nuvaxovid vaccine
Myocarditis/pericarditis	Information will be added to the Nuvaxovid data sheet. See the alert communication. Medsafe will continue to monitor this closely.

Definitions

Adverse event following immunisation (AEFI)

An AEFI is an untoward medical event which follows immunisation and does not necessarily have a causal relationship with the administration of the vaccine. The adverse event may be an unfavourable or unintended sign, abnormal laboratory finding, symptom or disease.

Serious adverse event following immunisation

An AEFI is considered serious if it:

• is a medically important event or reaction
• requires hospitalisation or prolongs an existing hospitalisation
• causes persistent or significant disability or incapacity
• is life threatening
• causes a congenital anomaly/birth defect
• results in death.

It is possible for different people to have experienced the same event but for the report to be serious for one person and non-serious for another person.

Adverse events of special interest (AESI)

An AESI is a pre-specified medically significant event that has the potential to be causally associated with the vaccine product based on past experience, the technology used to make the vaccine or the infection the vaccine is used to protect against. AESIs need to be carefully monitored and any potential association to vaccination confirmed by further analysis and studies.

Safety signal

Information on a new or known adverse event that may be caused by the vaccine and requires further investigation. Safety signals can be detected from a wide range of sources such as CARM reports, clinical studies and scientific literature.

Valid report

There are only four requirements for a valid AEFI report:

1. one patient identifier (eg, name, initials, gender, date of birth, age)
2. suspect medicine(s)
3. suspected reaction(s)
4. reporter details.

These four requirements are the minimum requirements. However, including more information in the report helps Medsafe to investigate the reaction more quickly. Reporting is easiest online.

More information

See the data sheets and consumer medicine information for the expected reactions for approved COVID-19 vaccines.

COVID-19 Vaccine Safety Monitoring Process

View Ministry of Health COVID-19 vaccine data

Latest listing of all cases received

The latest listing of AEFIs received is included in the attached spreadsheet. Medsafe advises patients NOT to make any decisions about vaccination based on information contained here.

Download AEFI-line-listing.xlsx (Excel, 9004 KB)